

21 January 2022

Dear Shareholder(s),

Elections of Means of Receipt and Language of Corporate Communications

Pursuant to the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Articles of Association of Everest Medicines Limited (the “**Company**”) in relation to the corporate communications (the “**Corporate Communication(s)**”) of the Company, the Company will make available the following options for you to elect the means of receipt and language of Corporate Communications of the Company in the future. Corporate Communication means any document to be issued by the Company for your information or action as defined under Rule 1.01 of the Listing Rules, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditor's report and, where applicable, its summary of financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

You may choose one of the options set out below:

- (1) to receive all future Corporate Communications in electronic form on the Company's website at www.everestmedicines.com instead of receiving printed copies, and to receive a printed notification letter for the publication of the relevant Corporate Communications on the website of the Company by post; or
- (2) to receive the printed English version of all future Corporate Communications by post only; or
- (3) to receive the printed Chinese version of all future Corporate Communications by post only; or
- (4) to receive both the printed English and Chinese versions of all future Corporate Communications by post.

To make your election, please mark “**X**” in the appropriate box in the enclosed reply form and sign and return it by post or by hand to the Company's share registrar in Hong Kong (the “**Hong Kong Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong. If you post your reply in Hong Kong, you may use the pre-paid mailing label in the reply form and need not affix a stamp on the envelope when returning your reply form. Otherwise, please affix an appropriate stamp.

If the Company does not receive a duly completed and signed reply form from you (or any other response from you indicating that you object to receiving Corporate Communications in electronic form on the Company's website) on or before 18 February 2022, you will be deemed, until you inform the Company otherwise by reasonable notice in writing to the Hong Kong Share Registrar at the above address or by email to everestmedicines.ecom@computershare.com.hk, to have elected to receive all future Corporate Communications in electronic form on the Company's website instead of receiving printed copies. In that event, when the Company publishes a Corporate Communication, a printed notification letter of the publication of the Corporate Communication on the Company's website will be sent to you. The notification will be sent to you by post at your address as it appears in the Company's register of members maintained by the Hong Kong Share Registrar.

You have the right at any time by reasonable prior notice in writing to the Company (send to the Hong Kong Share Registrar at the above address or by email to everestmedicines.ecom@computershare.com.hk) to elect (i) to receive future Corporate Communications in printed form instead of in electronic form on the Company's website (or in electronic form on the Company's website instead of in printed form) or (ii) to change the language in which you receive Corporate Communications in printed form. If you have elected (or are deemed to have elected) to receive Corporate Communications in electronic form on the Company's website and for any reason have difficulty in obtaining access to Corporate Communications on the Company's website, the Company will, upon request in writing or by email, send the Corporate Communications to you in printed form free of charge.

Please note that English and Chinese versions of all future Corporate Communications will be available (a) in printed form from the Company or the Hong Kong Share Registrar upon request; and (b) on the Company's website at www.everestmedicines.com and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

Should you have any queries in relation to this letter, please contact the service hotline of the Hong Kong Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays.

By Order of the Board of
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Reply Form 回條

To: Everest Medicines Limited (the “Company”)
(Stock Code: 1952)
 c/o Computershare Hong Kong Investor Services Limited
 17M Floor, Hopewell Centre, 183 Queen’s Road East,
 Wanchai, Hong Kong

致：雲頂新耀有限公司（「本公司」）
（股份代號：1952）
 經 香港中央證券登記有限公司
 香港灣仔皇后大道東 183 號
 合和中心 17M 樓

I/We would like to receive corporate communications[#] from the Company in the manner indicated below:

本人／我們欲以下列方式收取本公司之公司通訊[#]（「公司通訊」）：

(Please mark “X” in **ONLY ONE** of the following boxes)

(請從下列選擇中，僅在其中一個空格內劃上「X」號)

to receive all future Corporate Communications in electronic form on the Company’s website at www.everestmedicines.com instead of receiving printed copies, and to receive a printed notification letter for the publication of the relevant Corporate Communications on the website of the Company by post; **OR**

透過本公司網站 www.everestmedicines.com 收取所有將來的公司通訊電子本以代替收取印刷本，並以郵寄方式收取公司通訊文件已在網上刊發之通知信函印刷本；或

to receive the **printed English version** of all future Corporate Communications by post **ONLY**; **OR**

僅以郵寄方式收取所有日後公司通訊文件之英文印刷本；或

to receive the **printed Chinese version** of all future Corporate Communications by post **ONLY**; **OR**

僅以郵寄方式收取所有日後公司通訊文件之中文印刷本；或

to receive both the **printed English and Chinese versions** of all future Corporate Communications by post.

以郵寄方式同時收取所有日後公司通訊文件之英文及中文印刷本。

Signature(s)
簽名

Contact telephone number
聯絡電話號碼

Date
日期

Notes 附註：

- Please complete all your details clearly.
請 閣下清楚填寫所有資料。
- If the Company does not receive this duly completed and signed Reply Form from you (or any other response from you indicating that you object to receiving corporate communications in electronic form on the Company’s website) on or before 18 February 2022, you will be deemed to have elected to receive all future corporate communications in electronic form on the Company’s website instead of receiving them in printed form. All future corporate communications will be sent out in the manner specified in the Company’s letter dated 21 January 2022.
倘若本公司於 2022 年 2 月 18 日或之前尚未收到 閣下已適當地填妥並簽署的回條（或表示反對以電子方式於本公司網站收取公司通訊的回覆），閣下將被視為已同意只透過本公司網站收取將來的公司通訊電子本以代替收取印刷本。本公司將按 2022 年 1 月 21 日之本公司函件內所述之方式向 閣下發出所有將來的公司通訊。
- By electing to receive corporate communications in electronic form on the Company’s website instead of receiving them in printed form, you have expressly agreed that they may be sent or supplied to you by being made available on the Company’s website and have expressly waived the right to receive them in printed form.
在選擇透過本公司網站收取公司通訊電子本以代替收取印刷本後，閣下已明示同意放棄收取公司通訊印刷本的權利。
- If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign this Reply Form in order for it to be valid.
如屬聯名股東，則本回條應由該聯名股東於本公司股東名冊上名列首位者簽署，方為有效。
- The above instruction will apply to all future corporate communications sent to you unless and until you inform the Company otherwise by reasonable notice in writing to the Company c/o the Company’s share registrar in Hong Kong (the “Hong Kong Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or by email to everestmedicines.com@computershare.com.hk.
上述指示適用於將來向 閣下發出之所有公司通訊，直至 閣下向本公司發出合理時間的書面通知予本公司之香港證券登記處香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓或以電郵方式發送至 everestmedicines.com@computershare.com.hk 另作選擇為止。
- Shareholders shall have the right at any time by reasonable notice in writing to the Company (sent to the Hong Kong Share Registrar at the above address or by email to everestmedicines.com@computershare.com.hk) elect (i) to receive future corporate communications in printed form instead of in electronic form on the Company’s website (or in electronic form on the Company’s website instead of in printed form) or (ii) to change the language in which they receive corporate communications in printed form.
股東有權隨時以合理時間的書面通知（於上述地址）或以電郵方式發送至 everestmedicines.com@computershare.com.hk 通知香港證券登記處，選擇(i)收取本公司將來的公司通訊之印刷本，以取代於本公司網站登載的電子本（或收取於本公司網站登載的公司通訊電子本，以取代印刷本）或(ii)更改所收取的公司通訊印刷本的語言版本。
- For the avoidance of doubt, we do not accept any special instructions written on this Reply Form.
為免疑，任何在本回條上的額外書寫指示將不予處理。

[#] Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and financial statements contained in them), notices of meetings, listing documents, circulars and proxy forms.
公司通訊乃本公司向其證券持有人發出以供參照或採取行動的任何文件，包括但不限於年度和中期財務報告及其摘要報告（及其中包含的所有報告及財務報表）、會議通告、上市文件、通函及委任代表表格。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freepost No. 簡便回郵號碼：37

Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回本申請表格時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry 垂詢
Rate our service 評價
Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact